Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes.
Hoelzer
D
D
Dept. of Hematology, University of Frankfurt, FRG.
Ganser
A
A
Ottmann
O G
OG
Höffken
K
K
Becher
R
R
Lutz
D
D
Krieger
O
O
Diehl
V
V
Lathan
B
B
Boogaerts
M A
MA
D000328:Adult; D000368:Aged; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003115:Colony-Stimulating Factors / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004357:Drug Synergism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000494:pharmacology / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D011994:Recombinant Proteins; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor